Major Shareholder Files Intent to Sell $2.36M in Immunome Stock
IMNM has more than doubled off its 52-week low of $7.96.
Summary
A major institutional shareholder, ABHMC II, LLC, has filed a Form 144 indicating intent to sell $2.36 million of Immunome stock, continuing a trend of insider distribution.
Key Events · Ownership and Investor Activity · IMNM
-
Intent to Sell Shares
ABHMC II, LLC, a significant shareholder, has filed a Form 144 to sell 100,000 shares of Immunome common stock, valued at approximately $2.36 million.
-
Continuation of Selling Pattern
This filing is part of an ongoing pattern of insider and institutional selling, with ABHMC II, LLC having sold an additional 201,050 shares for $4.39 million in the past three months, and other insiders showing net distribution of over $6.4 million in the last 90 days.
-
Acquisition Details
The shares intended for sale were acquired through a private placement on October 3, 2023.
Analysis · IMNM · Life Sciences
A significant shareholder, ABHMC II, LLC, has filed an intent to sell an additional $2.36 million worth of Immunome stock. This follows recent sales by the same entity and other insiders, contributing to a pattern of distribution. While the company recently announced positive clinical trial results and an NDA submission, this ongoing selling pressure from a major institutional investor could create an overhang on the stock.
At the time of this filing, IMNM was trading at $24.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $7.96 to $27.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.